Clinical Trials Logo

Clinical Trial Summary

This study will compare aqueous humor dynamics in adults with primary open angle glaucoma that receive Selective Laser Trabeculoplasty (SLT).


Clinical Trial Description

Describe the background of the study. Include a critical evaluation of existing knowledge, and specifically identify the information gaps that the project is intended to fill. Laser trabeculoplasty is currently a well established treatment option for lowering the intraocular pressure in the management of open angle glaucoma1,2. The procedure involves placement of laser spots over the trabecular meshwork, possibly through a variety of laser types. Argon laser trabeculoplasty (ALT) has been the most widely utilized option for laser trabeculoplasty over the past few decades. Since its availability approximately a decade ago, Selective Laser Trabeculoplasty (SLT) is currently an additional option for doing laser trabeculoplasty. 3,4. Current evidence suggests that SLT achieves its interocular pressure (IOP) lowering effect without thermal damage to the trabecular meshwork5. The IOP lowering effect of SLT has been shown to be comparable to ALT over the long term6. In physiological terms, ALT has been shown to lower the IOP primarily by increasing the conventional outflow facility7. There are two putative mechanisms by which this may be facilitated8. Thermal coagulation and shrinkage by ALT may mechanically open up the adjacent trabecular meshwork and Schlemm's canal. Alternatively the delivery of laser energy may trigger biological processes and activation of matrix metalloproteinases in the microenvironment of trabecular meshwork that lead to a remodeling of tissues resulting in improved outflow facility. ALT uses argon or another thermal laser to photocoagulate tissues around the trabecular meshwork. The settings vary depending on the tissue response and pigmentation. Most clinicians use 600-1500mW, 50-100 spots, 50 micron spot size and 0.1 sec duration. Also, there is limited data on fluorophotometric and tonographic studies on ALT and none on SLT to the best of our knowledge. All available reference known to the investigators have been included in the list of references. The effect of SLT on the aqueous humor dynamics is currently unknown. Given the lack of demonstrable thermal damage on histopathologic examination5, it is unlikely that the effects of SLT could be mechanically mediated. There has been some suggestion of a potential interaction of IOP lowering effect when prostaglandins and SLT are used together9,10. This suggests that there could be a possible sharing of mechanisms between SLT and prostaglandins. The IOP lowering effect of SLT may be mediated in part by effects on uveoscleral pathways in addition to the trabecular outflow pathway. This study will determine the changes in aqueous humor dynamics produced by SLT that lead to its IOP lowering effect. SLT is a Q switched frequency doubled Nd:YAG laser. The duration is 3 nanoseconds and spot size 500 microns. Power varies from 0.5-1.5 mJ and total number of spots can be between 50-over 100. The mechanism of action may be disruption of melanosomes, but this has not been unequivocally proven yet. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01342406
Study type Observational
Source University of Nebraska
Contact
Status Completed
Phase
Start date September 1, 2010
Completion date November 1, 2013

See also
  Status Clinical Trial Phase
Completed NCT03284853 - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension Phase 3
Terminated NCT03611530 - CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma N/A
Not yet recruiting NCT06441643 - Next Generation Rocklatan Phase 2
Not yet recruiting NCT02868502 - Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma N/A
Completed NCT02272569 - STARflo European Safety and Efficacy Study N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT01936389 - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Phase 2
Completed NCT00941525 - Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure Phase 4
Completed NCT00539526 - Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase 4
Completed NCT00121147 - Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan N/A
Active, not recruiting NCT05035394 - Swedish Microinvasive Glaucoma Surgery Study (SMIGS) N/A
Completed NCT03450629 - Evaluation of Safety and Efficacy of PDP-716 Phase 3
Active, not recruiting NCT06061718 - Travoprost Intraocular Implant in Conjunction With Cataract Surgery Phase 3
Recruiting NCT05241938 - PSLT Compared to Prostaglandin Analogue Eye Drops N/A
Completed NCT02250612 - SYL040012, Treatment for Open Angle Glaucoma Phase 2
Completed NCT01937312 - Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Phase 4
Terminated NCT01983579 - TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Phase 4
Completed NCT01937299 - Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Phase 4
Completed NCT01229982 - A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma Phase 2
Recruiting NCT00440336 - Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma. N/A